Upgrade to Finviz Elite: Get our fastest platform speed, real-time data, and unlimited screening & charting. Start Free Trial

NVO

Novo Nordisk ADR

Mar 27 • 04:00PM ET

36.04

-0.36 -0.99 %

Healthcare • Drug Manufacturers - General • Denmark • NYSE

Peers: LLY MRK ABBV JNJ AMGN AZN-D PFE SNY BMY GSK

| Held by: PVAL PPH AVDE PID WCMI PINK AQEC APIE OZEM NVOH

Scroll to Statements

Index	-	P/E	10.39	EPS (ttm)	3.47	Insider Own	0.01%	Shs Outstand	3.37B	Perf Week	-1.34%
Market Cap	121.42B	Forward P/E	10.84	EPS next Y	3.33	Insider Trans	0.00%	Shs Float	3.37B	Perf Month	-4.20%
Enterprise Value	137.78B	PEG	-	EPS next Q	0.89	Inst Own	9.43%	Short Float	0.73%	Perf Quarter	-31.43%
Income	15.45B	P/S	2.60	EPS this Y	-11.36%	Inst Trans	0.30%	Short Ratio	1.03	Perf Half Y	-35.69%
Sales	46.77B	P/B	5.25	EPS next Y	3.12%	ROA	20.59%	Short Interest	24.70M	Perf YTD	-29.17%
Book/sh	6.87	P/C	28.64	EPS next 5Y	-0.23%	ROE	61.25%	52W High	81.44 -55.75%	Perf Year	-48.63%
Cash/sh	1.26	P/FCF	13.57	EPS past 3/5Y	26.28% 20.36%	ROIC	31.38%	52W Low	35.85 0.53%	Perf 3Y	-53.41%
Dividend Est.	1.66 (4.60%)	EV/EBITDA	6.09	Sales past 3/5Y	23.19% 19.21%	Gross Margin	80.90%	Volatility	2.46% 2.50%	Perf 5Y	6.34%
Dividend TTM	1.73 (4.79%)	EV/Sales	2.95	EPS Y/Y TTM	5.57%	Oper. Margin	41.17%	ATR (14)	1.29	Perf 10Y	34.55%
Dividend Ex-Date	Mar 30, 2026	Quick Ratio	0.57	Sales Y/Y TTM	11.11%	Profit Margin	33.03%	RSI (14)	30.24	Recom	2.56
Dividend Gr. 3/5Y	28.28% 20.66%	Current Ratio	0.80	EPS Q/Q	3.95%	SMA20	-4.46%	Beta	0.75	Target Price	47.71
Payout	38.07%	Debt/Eq	0.67	Sales Q/Q	0.66%	SMA50	-21.77%	Rel Volume	0.61	Prev Close	36.40
Employees	68794	LT Debt/Eq	0.61	Earnings	Feb 04 BMO	SMA200	-33.19%	Avg Volume	24.01M	Price	36.04
IPO	Apr 30, 1981	Option/Short	Yes / Yes	EPS/Sales Surpr.	3.40% 3.10%	Trades		Volume	14,608,900	Change	-0.99%

Date	Action	Analyst	Rating Change	Price Target Change
Mar-26-26	Initiated	Wolfe Research	Peer Perform
Mar-18-26	Initiated	Bernstein	Underperform
Mar-18-26	Initiated	Bernstein	Outperform	$175
Mar-10-26	Downgrade	TD Cowen	Buy → Hold	$42
Mar-03-26	Upgrade	Morgan Stanley	Underweight → Equal-Weight	$40
Mar-02-26	Downgrade	Goldman	Buy → Neutral	$41
Feb-24-26	Downgrade	Kepler	Buy → Hold
Feb-24-26	Downgrade	JP Morgan	Overweight → Neutral
Feb-23-26	Downgrade	Deutsche Bank	Buy → Hold
Feb-12-26	Upgrade	Jefferies	Underperform → Hold
Jan-27-26	Initiated	Citigroup	Neutral
Dec-08-25	Downgrade	Argus	Buy → Hold
Oct-27-25	Resumed	Jefferies	Underperform
Oct-01-25	Upgrade	HSBC Securities	Hold → Buy
Sep-29-25	Downgrade	Morgan Stanley	Equal-Weight → Underweight	$47
Sep-17-25	Upgrade	Berenberg	Hold → Buy
Sep-16-25	Upgrade	Rothschild & Co Redburn	Neutral → Buy
Sep-09-25	Upgrade	Bernstein	Mkt Perform → Outperform
Aug-13-25	Upgrade	BNP Paribas Exane	Underperform → Neutral	$54
Aug-05-25	Downgrade	UBS	Buy → Neutral

Show Previous Ratings

Mar-27-26 04:00AM	Novos FDA voucher victory; biotechs rigid glass ceiling (Pharma Voice)
Mar-26-26 09:40AM	Wave Plunges More Than 50% After Obesity Shot Falls Short (Bloomberg)
08:30AM	Novo Nordisk GLP-1 pipeline shows promise but oral drug trends give analysts pause (Proactive)
Mar-24-26 12:15PM	Jefferies trims Novo Nordisk target as GLP-1 pricing erosion and oral Wegovy launch uncertainty cloud first quarter (Proactive)
Mar-23-26 03:28PM	India Opened the Floodgates on Weight-Loss Generics (Moby)
03:45AM	Loading…
Mar-21-26 03:45AM	Beijing courts Eli Lilly as weight-loss drug race drives $3bn China commitment (Investing.com)
Mar-20-26 02:10PM	India Sees 42 Drugmakers Launch Generic Semaglutide After Patent Expiry (GuruFocus.com)
01:51PM	Novo Nordisks Wegovy HD secures FDA greenlight amid patent expiries (Pharmaceutical Technology)
12:56PM	What's Going On With Novo Nordisk Friday (GuruFocus.com)
12:14PM	Weight-loss drugs are changing the way people dress. These companies stand to benefit. (MarketWatch)
08:08AM	Novo Nordisk Wins U.S. Approval for Higher-Dose Wegovy (GuruFocus.com)
07:12AM	Lilly GLP-1 drug rivals Novo's pipeline treatment on gut side effects but throws up skin concern (Proactive)
Mar-19-26 03:49PM	Novo Tries New Japan Strategy To Boost Demand (GuruFocus.com)
02:42PM	A high dose of Wegovy helped people lose 21% of their weight. It was just approved. (MarketWatch)
12:04PM	FDA approves Novo Nordisk's new Wegovy HD injection, delivering the highest weight loss to date for a Wegovy injection, adding to its already expansive clinical profile (PR Newswire)
10:09AM	Loading…
10:09AM	Novo uses FDA voucher to win speedy approval of higher-dose Wegovy (BioPharma Dive)
08:23AM	Novo Nordisk Targets Japan Self-Pay Market as Only 14,000 Access Obesity Drugs (GuruFocus.com)
Mar-18-26 02:29PM	Analysis-TrumpRx lists many medicines at prices higher than paid in UK (Reuters)
11:42AM	It's time to rethink how we define obesity as millions turn to GLP-1s (MarketWatch)
Mar-17-26 04:21PM	HSBC Downgrades Eli Lilly, Cuts PT to $850, Flags Obesity Market Risks (GuruFocus.com)
02:28PM	Lilly gets rare downgrade as analysts question hype over GLP-1 pills and Zepbound's cash sales (MarketWatch)
02:19PM	Eli Lilly Stock Gets Downgraded. It Faces Stiff Headwinds After Strong Run-Up. (Barrons.com)
09:15AM	Rival GLP-1 pill matches Wegovy weight loss data, adding to competitive pressure on Novo Nordisk (Proactive)
Mar-16-26 09:33AM	India Semaglutide Patent Expiry Could Drive 50% Price Drop in Weight-Loss Drugs (GuruFocus.com)
07:35AM	Structures GLP-1 pill shows best-in-class potential in obesity trial (BioPharma Dive)
Mar-14-26 05:30AM	Investing.coms stocks of the week (Investing.com)
Mar-13-26 04:45PM	Hims Shares Notch Record Week as Novo Pact Spurs Optimism (Bloomberg)
04:00AM	Novo regained weight loss footing in the pill arena but Lilly is coming (Pharma Voice)
04:00AM	Keytrudas reign continues; pharmas megadeal drought (Pharma Voice)
Mar-12-26 02:50PM	Hims & Hers Stock Jumps After Novo Nordisk Deal. What It Means for Drugmaker (GuruFocus.com)
11:22AM	Loading…
11:22AM	Wegovy portfolio growth shifts to the pill as injectable sales forecast to plateau (Pharmaceutical Technology)
10:57AM	Should You Chase the Rally in Hims & Hers Stock Today? (Barchart)
09:12AM	Novo Nordisk stock slump hits value of controlling shareholder (GuruFocus.com)
07:40AM	Lilly warns GLP-1 knockoffs may be dangerous, escalating war with compounders (BioPharma Dive)
Mar-11-26 04:37PM	Lilly Warns Some Medicare GLP-1 Costs Could Exceed $50 (GuruFocus.com)
02:14PM	Eli Lilly Stock In Spotlight -- Announces $3 Billion Investment Plan in China (GuruFocus.com)
09:00AM	Lilly Flags A Catch In $50 GLP-1 Plan (GuruFocus.com)
02:27AM	Ozempic Maker Novo Nordisk Faces Another Strike By US FDA With Warning Letter Over 'Systemic Failures' In Safety Reporting (Benzinga)
Mar-10-26 04:04PM	Novo Nordisk Warned by FDA Over Adverse Event Reporting (GuruFocus.com)
03:02PM	What's Driving Attention Behind These Trending Stocks? MRVL, STRL, HIMS (Zacks)
02:42PM	Hims & Hers Stock Upgraded After Novo Nordisk Agreement. Why It Isn't a Buy Yet. (Barrons.com)
02:39PM	Eli Lilly Says Some Medicare GLP-1 Patients May Pay Above $50 Under New CMS Model (GuruFocus.com)
02:38PM	Novo Nordisk A/S (NVO) Expands Manufacturing to Support Rising Global Demand for GLP-1 Drugs (Insider Monkey)
02:03PM	Patience Pays: Hims & Hers Surges on News of Novo Nordisk Deal (MarketBeat)
01:01PM	What's Fueling The Rise In Hims & Hers Health Stock Today? (Benzinga)
12:45PM	GLP-1 weight-loss drug race heats up as new rival matches Wegovy results with fewer side effects (Proactive)
12:05PM	Wall Street Gets Less Bearish on Hims & Hers After Novo Nordisk Truce. Stock Gains Could Still Be Limited. (Barrons.com)
10:23AM	Wall Street Pulls Back on Novo Nordisk and Jefferies While Talkspace Heads for Exit (24/7 Wall St.)
09:34AM	Qualcomm downgraded, Rivian upgraded: Wall Street's top analyst calls (The Fly)
08:21AM	Novo Nordisk downgraded as pipeline not poised to blunt semaglutide LOE (Investing.com)
08:06AM	Here Are Tuesday's Top Wall Street Analyst Research Calls: AT&T, Amgen, CrowdStrike, Gilead, Hims & Hers, Intuit, Lowe's,Qualcomm, Rivian, Strategy and More (24/7 Wall St.)
07:40AM	Novo and Hims & Hers become partners to end legal feud (Pharmaceutical Technology)
05:48AM	Ozempic maker Novo Nordisk gets another downgrade. The end's in sight for its duopoly status, says TD Cowen. (MarketWatch)
Mar-09-26 04:18PM	Uber expands Women Preferences, Hims & Hers stock skyrockets (Yahoo Finance Video)
04:02PM	Novo Nordisk deal lets Hims sell Wegovy and Ozempic, drops lawsuit (USA TODAY)
03:32PM	Hims & Novo Call a Truce, Hims Gets Exactly What It Wanted (Moby)
03:30PM	Hims & Hers rockets higher on potential Novo Nordisk deal (GuruFocus.com)
03:23PM	Stock Of The Day: Will Hims & Hers Go Into Another Short Squeeze? (Benzinga)
02:54PM	Hims & Hers Jumps 47% as Novo Nordisk Weighs New Weight-Loss Drug Partnership (GuruFocus.com)
02:34PM	Nasdaq stays green as Middle East war sends oil above $103 (Proactive)
02:27PM	Hims and Novo End Feud With Obesity Drug Deal (GuruFocus.com)
01:18PM	Novo Nordisk strikes deal for Hims to sell Wegovy and Ozempic (Reuters Videos)
01:17PM	Hims & Hers Shares Surge on Novo Nordisk Deal Report (GuruFocus.com)
01:11PM	Hims & Hers stock skyrockets 40% as Novo Nordisk ends feud, agrees to sell Ozempic and Wegovy on platform (MarketWatch)
12:51PM	Hims & Hers Stock Jumps on Reports Novo Nordisk Obesity Deal (GuruFocus.com)
12:15PM	Hims & Hers Stock Soars. Its Weight-Loss Drug Battle With Novo Nordisk Takes a Surprising Twist. (Barrons.com)
11:16AM	Pre-Markets in the Red as Geopolitical Tensions Escalate (Zacks)
11:13AM	Hims partners with Novo Nordisk, Live Nation settles antitrust suit (Yahoo Finance Video)
11:08AM	Hims & Hers stock surges as Novo Nordisk says it will distribute weight-loss drugs on platform (Yahoo Finance)
11:04AM	Hims & Hers partners with Novo Nordisk to sell Wegovy and Ozempic, ending dispute (Proactive)
10:35AM	HIMS Stock Eyes Best Day Ever After Dispute Dissolution (Schaeffer's Research)
10:18AM	Hims & Hers Health and Novo Nordisk end lawsuit over weight loss medications, enter collaboration (Associated Press Finance)
10:17AM	Pre-Markets Down as Middle East Tensions Remain (Zacks)
10:01AM	Hims & Hers agrees to stop selling compound versions of Novo Nordisk's Wegovy and other weight-loss drugs, ending suit (Associated Press Finance)
09:53AM	Hims & Hers Catapults After Settling Its Bloody Saga With Novo Nordisk (Investor's Business Daily)
09:52AM	Novo Nordisk to Sell Weight-Loss Drugs Through Hims & Hers (The Wall Street Journal)
09:38AM	Hims & Hers Stock Pops on a Deal With Rival Novo NordiskWhat You Need to Know (Investopedia)
09:35AM	Hims & Hers Stock Surges as Novo Nordisk Deal Ends Legal Dispute (The Wall Street Journal)
09:34AM	Hims And Hers Surges 40% On Deal To Sell Novo Nordisk Obesity Drugs (Investor's Business Daily)
09:05AM	NVO Stock Sheds Nearly $50B in Market Cap in a Month: Should You Sell? (Zacks)
09:02AM	Hims & Hers will sell real Ozempic in deal with Novo Nordisk (Quartz)
08:09AM	Roche's Breast Cancer Drug Falls Short In Phase 3 Study (Benzinga)
07:04AM	Hims & Hers, Novo Nordisk Weight-Loss Drug Deal Ends Legal Feud, Stock Soars (Benzinga)
07:00AM	Hims And Hers Surges Over 50% On Deal To Sell Novo Nordisk Obesity Drugs (Investor's Business Daily)
06:25AM	These Stocks Are Todays Movers: Chevron, Hims & Hers, Carnival, Delta, Newmont, Vertiv, and More (Barrons.com)
06:06AM	Hims & Hers Shares Double on Report of Wegovy Tie-Up (The Wall Street Journal)
05:43AM	Stocks to Watch Monday: Lamb Weston, Carnival, Pfizer, Hims & Hers (The Wall Street Journal)
05:34AM	Hims soars 44% on report Novo Nordisk to sell weight-loss drugs on its platform (Investing.com)
05:28AM	Stock Market Today: Dow Jones, S&P 500 Futures Plunge As Oil Prices Jump, Trump Dismisses 'Short Term' Spike-Hims & Hers, Ovintiv, Uniqure In Focus (Benzinga)
04:32AM	Morgan Stanley Upgrades Novo Nordisk A/S (NVO) to Equal Weight From Underweight - Here's Why (Insider Monkey)
Mar-07-26 10:56AM	Hims & Hers Surprise Rescue: Stock Explodes 40% on GLP-1 Truce (24/7 Wall St.)
Mar-06-26 09:52PM	Novo Nordisk And Hims & Hers End Bitter Legal Feud With Surprise Weight-Loss Drug Deal: Report (Benzinga)
02:46PM	Novo Nordisk (NVO) Reports 10% Sales Growth as Obesity Care Hits DKK 82B (Insider Monkey)
01:09PM	Study Says Ozempic Knockoffs Could Cost $3 (GuruFocus.com)
11:28AM	Roche Advances Obesity Pipeline as Petrelintide Meets Phase II Goal (Zacks)
09:00AM	Novo Nordisk A/S (NVO) Is a Trending Stock: Facts to Know Before Betting on It (Zacks)
08:41AM	Zealand Pharma CEO Says Most-Tolerable Drugs Will Be Next to Win in Obesity Market (The Wall Street Journal)
08:14AM	China Clears Weight-Loss Shot As Pfizer Enters Crowded Market (Benzinga)
06:47AM	Roche's Obesity Drug Shows Promise But Trails GLP-1 Giants Novo Nordisk And Eli Lilly (Benzinga)
04:20AM	Zealand Pharma Shares Plunge After Obesity Drug Candidate Disappoints in Trial (The Wall Street Journal)

Novo Nordisk A/S is a global healthcare company, which engages in the discovery, development, manufacturing and marketing of pharmaceutical products. It operates through the Diabetes and Obesity Care and Rare Disease segments. The Diabetes and Obesity Care segment includes diabetes, obesity, cardiovascular, and emerging therapy areas. The Rare Disease segment refers to rare blood disorders, rare endocrine disorders, and hormone replacement therapy. The company was founded by Harald Pedersen and Thorvald Pedersen in 1923 is headquartered in Bagsvaerd, Denmark.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Novo Nordisk A/S	10% Owner	May 30 '25	Proposed Sale	2.14	921,897	1,972,859		May 30 08:31 AM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

NVO

Novo Nordisk ADR

Upgrade your FINVIZ experience